N-Acetyl Cysteine for Multiple Sclerosis
(MSNAC Trial)

Recruiting in Palo Alto (17 mi)

Overseen byDaniel A Monti, MD, MBA

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Thomas Jefferson University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing whether NAC, a cell-protecting supplement, can help MS patients by reducing cell damage in the brain. MS patients often experience nerve cell damage, and NAC may help by boosting a protective substance called glutathione. NAC has been explored in previous studies for its potential to improve brain glucose metabolism and blood flow in MS patients.

Eligibility Criteria

This trial is for adults with relapsing remitting or progressive Multiple Sclerosis who can travel to Philadelphia. They should be physically independent and either not on MS medication, planning to start one, or on a stable regimen of certain disease-modifying drugs. Participants must use effective contraception if applicable and cannot have conditions that interfere with the study.

Inclusion Criteria

I am 18 years old or older.

I am using or will use effective birth control during the study.

Participants must be able to complete study procedures in the greater Philadelphia area

See 2 more

Exclusion Criteria

I've had brain surgery that may affect brain scans.

I take daily medication to manage my asthma.

You weigh more than the maximum weight allowed on the table.

See 18 more

Treatment Details

Interventions

N-acetyl Cysteine (Antioxidant)

Trial OverviewThe trial tests whether N-acetyl cysteine (NAC) supports brain function in MS patients using advanced imaging techniques like PET-MRI scans. It aims to measure changes in cerebral metabolism and myelin structure after administering NAC.

Participant Groups

2Treatment groups

Active Control

Group I: N-acetyl Cysteine CohortActive Control1 Intervention

Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 500mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)

Group II: Control CohortActive Control1 Intervention

Standard of Care Treatment